Anti-metabolic disorder plant peptide group and uses thereof

Abstract

To provide an anti-metabolic disorder plant peptide group, and to provide uses thereof.SOLUTION: The present invention provides an anti-metabolic disorder plant peptide group and uses thereof. Specifically, the anti-metabolic disorder plant peptide group disclosed in the present invention simultaneously possess the activity of controlling blood glucose, blood lipids, and blood pressure. Therefore, administering an effective amount of the anti-metabolic disorder plant peptide group to an individual can effectively prevent or ameliorate various metabolic disorders such as high blood pressure, high blood lipids, and high blood glucose. The anti-metabolic disorder plant peptide group is obtained by isolation from a primary product of plant raw materials.SELECTED DRAWING: Figure 12

Description

[Technical Field]

[0001] The present invention relates to a composition composed of a low molecular weight protein, and in particular to antimetabolic disorder plant peptides and uses thereof. [Background technology]

[0002] As modern people become more health conscious, consumers are no longer limited to purchasing basic dietary supplements such as vitamins and minerals, but are also purchasing dietary supplements with specific functions to meet their needs.With the advancement of biotechnology, many manufacturers are using special manufacturing processes such as fermentation and hydrolysis to extract active ingredients with specific functions from food, and then using these as active ingredients in dietary supplements to enhance the effectiveness of promoting health.

[0003] Statistics show that more than a quarter of people in Taiwan suffer from metabolic disorders such as high blood pressure, high blood sugar, and high blood lipids. The causes of these metabolic disorders are not limited to genetics; they are also related to individual diet and lifestyle habits. Factors such as an imbalance between work and rest, high levels of stress in daily life, lack of exercise, and a diet dominated by fried foods are also contributing factors. While metabolic disorders may not have a significant impact on health in the short term, they can lead to serious illnesses such as stroke, heart disease, and diabetes in the long term. However, because changing diet and lifestyle habits is difficult, many people choose to take nutritional supplements to control their blood pressure, blood sugar, and blood lipids. However, there is currently no single nutritional supplement on the market that can simultaneously improve blood pressure, blood sugar, and blood lipids. Summary of the Invention [Problem to be solved by the invention]

[0004] The present invention provides a group of peptides from plants with metabolic disorders and uses thereof. The peptides from plants with metabolic disorders contain multiple small active peptides, which have the ability to simultaneously control blood glucose, blood lipids, and blood pressure through the synergistic effect of the combined small active peptides. Therefore, by administering the peptides from plants with metabolic disorders disclosed in the present invention, it is possible to simultaneously and effectively improve or treat diseases related to hypertension, hyperglycemia, and hyperlipidemia. [Means for solving the problem]

[0005] To achieve the above-mentioned objectives, the present invention discloses a group of plant peptides for metabolic disorders, which are isolated from the primary products of plant materials and contain at least six small molecular weight peptides, which can exert synergistic effects with each other and can simultaneously improve or treat various metabolic diseases associated with imbalances in metabolic indicators such as blood pressure, blood lipids, and blood glucose by controlling the MAPK pathway, IRS / p-IR / PI3K / Akt pathway, etc. in individuals.

[0006] Here, the primary product of the plant material is obtained by sequentially performing two-stage extraction processes on the plant material, the first extraction process being a water extraction process and the second extraction process being a supercritical extraction process.

[0007] In other words, by administering to an individual an effective amount of the antimetabolic disorder plant peptides disclosed in the present invention or a composition containing the antimetabolic disorder plant peptides, it is possible to simultaneously combat or improve various metabolic disorders, particularly to simultaneously treat or prevent diseases related to hypertension, hyperglycemia, and hyperlipidemia, wherein the effective amount is at least 5 mg / kg / day.

[0008] In one embodiment of the present invention, the group of peptides from antimetabolic disorder plants includes peptides with molecular sizes between 300 Da and 3000 Da, which are represented by wavelength ranges (L1) to (L6) in a high-performance liquid chromatogram, wherein the retention time in the wavelength range (L1) is 10.5 to 11.5 minutes, the retention time in the wavelength range (L2) is 12.5 to 13.5 minutes, the retention time in the wavelength range (L3) is 14.5 to 15.5 minutes, the retention time in the wavelength range (L4) is 16.5 to 17.5 minutes, the retention time in the wavelength range (L5) is 17.5 to 18.5 minutes, and the retention time in the wavelength range (L6) is 24.5 to 25.5 minutes.

[0009] The HPLC chromatogram was obtained by pretreating the primary product of the plant material and then analyzing it using a HPLC under specified analytical conditions, as follows: the detection wavelength was 220 nm, the separation column was a C18 column (RP-C18), the column temperature was 60°C, eluent A was 5% acetonitrile containing 0.10% trichloroacetic acid, eluent B was 95% acetonitrile containing 0.085% trichloroacetic acid, and the mobile phase included 10-20% eluent B used for 0-10 minutes, 20-30% eluent B used for 10-25 minutes, and 30-60% eluent B used for 20-60 minutes.

[0010] In another embodiment of the present invention, the pretreatment step includes dissolving the primary product of the plant material in 30% acetonitrile, followed by ultrasonic extraction to obtain a supernatant, and filtering the supernatant to obtain a filtrate, which is used for high performance liquid chromatography.

[0011] Here, in the above-mentioned pretreatment step, filtration is carried out using a filter medium with pores of 0.20 to 0.25 μm, and the filter medium may be a filter membrane or a mesh screen.

[0012] In another embodiment of the present invention, the molecular size of the peptides contained in the group of peptides from antimetabolic disorder plants and represented by the wavelength ranges (L1) to (L6) is between 700 Da and 2400 Da. [Brief explanation of the drawings]

[0013] [Figure 1] Chromatogram analysis results of the peptide group (1), which is a product extracted from bitter melon 1. [Figure 2] Chromatogram analysis results of peptide group (2), which is a product extracted from watermelon 1. [Figure 3] Chromatogram analysis results of peptide group (3), which is a product extracted from watermelon 2. [Figure 4] Chromatogram analysis results of peptide group (4), which is a product extracted from pumpkin 1. [Figure 5] Chromatogram analysis results of peptides (5), which are products extracted from pumpkin 2. [Figure 6] Chromatogram analysis results of the peptide group (6), which is a product extracted from bitter melon 2. [Figure 7] Chromatogram analysis results of peptides (7), which are products extracted from Triticum vulgare 1. [Figure 8] This is the result of chromatogram analysis of the peptide group (8), which is a product extracted from Triticum vulgare 2. [Figure 9] Chromatogram analysis results of the peptide group (9), which is a product extracted from bitter melon 3. [Figure 10] Chromatogram analysis results of the peptide group (10), which is a product extracted from bitter melon 4. [Figure 11] Chromatogram analysis results of the peptide group (11), which is a product extracted from bitter melon 5. [Figure 12] 2 shows the results of comparing the chromatogram in FIG. 1 with the chromatograms obtained by measuring comparative samples 1 to 7. [Figure 13] This shows the results of an analysis of fasting blood glucose levels in mice of each group after the 8th week of the test. [Figure 14] This shows the results of analyzing blood glycated hemoglobin in mice of each group after the 8th week of the test. [Figure 15] This shows the results of an analysis of fasting blood glucose levels in mice of each group after the 8th week of the test. [Figure 16] This shows the results of an analysis of the body weight of mice in each group after the 8th week of the test. [Figure 17] This shows the results of analyzing body fat in mice of each group after the 8th week of the test. [Figure 18] This shows the results of blood triglyceride analysis for mice in each group after the 8th week of the test. [Figure 19] This shows the results of analysis of total cholesterol in the blood of mice in each group after the 8th week of the test. [Figure 20] This shows the results of analyzing blood LDL cholesterol in mice of each group after the 8th week of the test. [Figure 21] This shows the results of an analysis of postprandial blood glucose changes in subjects of each group. [Figure 22] This shows the results of an analysis of the area under the blood glucose curve for subjects in each group 2 hours after a meal. DETAILED DESCRIPTION OF THE INVENTION

[0014] The present invention discloses a group of peptides from antimetabolic disorder plants and uses thereof. Specifically, the group of peptides from antimetabolic disorder plants disclosed in the present invention is obtained by separating it from the primary product of plant raw materials, and the group of peptides from antimetabolic disorder plants consists of peptides with molecular sizes between 300 Da and 3000 Da, which are indicated in the wavelength ranges (L1) to (L6) with retention times of 10.5 to 25.5 minutes in a high-performance liquid chromatogram.

[0015] Here, the high performance liquid chromatogram is obtained by subjecting the primary product of the plant raw material to a pretreatment step and then subjecting it to high performance liquid chromatography under predetermined analytical conditions.

[0016] Specifically, the group of antimetabolic disorder plant peptides disclosed in the present invention is obtained by separating from the primary product of plant raw material, and the primary product of plant raw material is obtained by sequentially subjecting the plant raw material to aqueous extraction and supercritical extraction, and the plant raw material has at least one of the following properties: inhibiting dipeptidyl peptidase 4, inhibiting α-amylase, inhibiting GLUT2, inhibiting SGLT1, inhibiting α-glucosidase, and controlling insulin.

[0017] Here, the plant material is, for example, a gourd plant such as watermelon, pumpkin, bitter melon, or bottle gourd.

[0018] The antimetabolic disorder plant peptides disclosed in this invention have the ability to reduce blood sugar, blood pressure, blood lipids, adipogenesis, etc., so by administering an effective amount of the antimetabolic disorder plant peptides or a composition containing the antimetabolic disorder plant peptides to an individual, it is possible to achieve the effect of simultaneously and effectively improving indicators related to metabolic diseases, thereby achieving the alleviation or treatment of diseases related to hyperglycemia, high blood lipids, and hypertension, such as diabetes, kidney disease, hypertension, and dyslipidemia, and reducing the risk of developing complications or symptoms related to the above-mentioned diseases.

[0019] The "primary product of plant material" as used in this invention refers to a product obtained by subjecting plant material to a combined process of water extraction and supercritical extraction, and removing residues and / or residuals, which contains the antimetabolic disorder plant peptide group disclosed in this invention.

[0020] The "plant material" according to the present invention is selected from the group consisting of Amaranthus sp., Phaseolus sp., Glycine sp., Avena sp., Cucurbitaceae, Cumin, Chenopodium sp., Orus, Juglans sp., Hordeum sp., Spinacia sp., Vugna sp., Triticum sp., Linum sp., Phalaris sp., Moringa sp., Theobroma sp., Zea mays, and the like. They are derived from plants classified as Bitter melon, Triticum aestivum, cucumber, pumpkin, gourd, watermelon, live ginger, bitter gourd, Zinnia elegans, Medicago truncatula, grapes, grapefruit, elderberry (Sambucus nigra), Arabidopsis thaliana, and rice.

[0021] The term "composition" as used herein refers to a composition containing 0.001% to 100% of the antimetabolic disorder plant peptides disclosed herein. If the composition does not consist entirely of the antimetabolic disorder plant peptides disclosed herein, it further contains a vehicle and / or excipient acceptable for pharmaceuticals or foods. The composition can be prepared in various dosage forms, such as tablets, powders, and aqueous solutions, as needed, and in various dosages depending on parameters such as administration needs, administration targets, and administration frequency. For example, the composition can be a dietary supplement, food, or drug.

[0022] The term "effective amount" as used herein refers to the minimum dose at which the antimetabolic disorder plant peptides disclosed in the present invention exert their activity in an individual.

[0023] The antimetabolic dysbiosis plant peptides disclosed in the present invention can be stably isolated from various types of plant materials and can simultaneously have the effects of lowering blood glucose, reducing body weight, reducing body fat, lowering blood triglycerides, lowering blood total cholesterol and blood LDL cholesterol, and lowering blood pressure. That is, by administering an effective amount of the antimetabolic dysbiosis plant peptides disclosed in the present invention or a composition containing the antimetabolic dysbiosis plant peptides to an individual, diseases caused by metabolic disorders of blood lipids, blood pressure, and blood glucose can be simultaneously and effectively alleviated or ameliorated, and various metabolic diseases can be simultaneously prevented or ameliorated, thereby reducing the discomfort consumers experience when taking various different dietary supplements and reducing the risk of interactions with dietary supplements and / or drugs. [Example]

[0024] The antimetabolic disorder plant peptides disclosed in the first embodiment of the present invention comprise a group of peptides, each consisting of a plurality of functional low molecular weight peptides isolated from a primary product of plant material, which is obtained by sequentially extracting bitter melon from a water extract and then a supercritical fluid extract. The antimetabolic disorder plant peptides are peptides represented by the wavelength ranges (L1) to (L6) in Figure 1, with retention times between 10.5 and 25.5 minutes and molecular weights between 300 and 3,000 Da.

[0025] Here, the wavelength ranges (L1) to (L6) were obtained by performing a pretreatment process on the primary product of the plant material and then analyzing it using a high-performance liquid chromatograph under specified analytical conditions, which included the following: detection wavelength of 220 nm, separation column of a C18 column (RP-C18), column temperature of 60°C, eluent A being 5% acetonitrile containing 0.10% trichloroacetic acid, eluent B being 95% acetonitrile containing 0.085% trichloroacetic acid, and the mobile phase including 10-20% eluent B used for 0-10 minutes, 20-30% eluent B used for 10-25 minutes, and 30-60% eluent B used for 20-60 minutes.

[0026] The retention time in the wavelength range (L1) is 10.5 to 11.5 minutes, the retention time in the wavelength range (L2) is 12.5 to 13.5 minutes, the retention time in the wavelength range (L3) is 14.5 to 15.5 minutes, the retention time in the wavelength range (L4) is 16.5 to 17.5 minutes, the retention time in the wavelength range (L5) is 17.5 to 18.5 minutes, and the retention time in the wavelength range (L6) is 24.5 to 25.5 minutes.

[0027] The pretreatment process includes the following steps:

[0028] Step a: The primary product of the plant material is dissolved in 30% acetonitrile, and then subjected to ultrasonic extraction to obtain a supernatant.

[0029] Step b: The supernatant is filtered to obtain a filtrate for high performance liquid chromatography.

[0030] Each wavelength range (L1) to (L6) in Figure 1 was analyzed by gel permeation chromatography (GPC). Further, by comparison with the GPC chromatograms of standard compounds, the molecular weights of each wavelength range (L1) to (L6) were estimated and confirmed to be between 300 and 3000 Da. The standards used were cytidine (molecular weight 243 Da), vitamin B12 (molecular weight 1350 Da), aprotinin (molecular weight 6500 Da), cytochrome (molecular weight 12000 Da), and myoglobin (molecular weight 17600 Da). The order of molecular weight appearance of these substances was myoglobin (10.226 min), cytochrome (10.658 min), aprotinin (11.864 min), vitamin B12 (13.787 min), and cytidine (14.835 min).

[0031] In addition, a simulated digestion test was conducted on the peptides from plants with antimetabolic disorders, and the difference in area in each wavelength range before and after the test was analyzed by high performance liquid chromatography. The results are shown in Table 1.

[0032] Table 1: Analysis results for each wavelength range (L1 to L6) in Figure 1 JPEG2025174570000002.jpg52151 [Example]

[0033] To demonstrate the stable isolation of peptides from antimetabolic plant proteins disclosed in the present invention, in the second example disclosed in the present invention, various Cucurbitaceae plants, including pumpkin, watermelon, bitter melon, and trifoliate, were prepared and subjected to aqueous extraction and supercritical fluid extraction, respectively, to obtain primary extracts from the plant materials. The primary extracts from each plant material were treated according to the pretreatment process described above and then analyzed by high-performance liquid chromatography under the analytical conditions described above, resulting in the chromatograms shown in Figures 2 to 11. In each figure, the numbers following the Cucurbitaceae plants are used to distinguish between different batches or sources of the same Cucurbitaceae plants. The content of each wavelength band in each chromatogram was then analyzed, as shown in Table 2 below.

[0034] As can be seen from the chromatograms in Figures 2 to 11, wavelength ranges (L1) to (L6) appeared between retention times of 10.5 to 25.5 minutes, of which the retention time of wavelength range (L1) was 10.5 to 11.5 minutes, the retention time of wavelength range (L2) was 12.5 to 13.5 minutes, the retention time of wavelength range (L3) was 14.5 to 15.5 minutes, the retention time of wavelength range (L4) was 16.5 to 17.5 minutes, the retention time of wavelength range (L5) was 17.5 to 18.5 minutes, and the retention time of wavelength range (L6) was 24.5 to 25.5 minutes.

[0035] Table 2: Contents of wavelength ranges (L1) to (L6) in Figures 2 to 11 JPEG2025174570000003.jpg162167

[0036] As can be seen from the chromatograms shown in Figures 1 to 11, the group of peptides from antimetabolic disorder plants disclosed by the present invention can be stably expressed in the primary products of each batch of plant raw material, and can be stably expressed in all different types of plant raw material, which clearly shows that the group of peptides from antimetabolic disorder plants disclosed by the present invention is available and reproducible. [Example]

[0037] The antimetabolic disorder plant peptides disclosed in the third embodiment of the present invention are similar to those in the above-mentioned embodiments, except for the pretreatment process carried out on the primary product of the plant material, which is as follows:

[0038] The primary product of the plant material was dissolved in 30% acetonitrile and then subjected to a first ultrasonic extraction. The extraction time was 20 minutes, the water bath temperature was lower than room temperature, and the mixture was centrifuged at 9000 rpm for 5 minutes to obtain a first supernatant and a first precipitate. The first precipitate was then dissolved in 30% acetonitrile and then subjected to a first ultrasonic extraction. The extraction time was 20 minutes, the water bath temperature was lower than room temperature, and the mixture was centrifuged at 9000 rpm for 5 minutes to obtain a second supernatant. The first and second supernatants were collected and filtered through a 0.20-0.25 μm pore membrane. The filtrate was suitable for subsequent high-performance liquid chromatography.

[0039] In addition, to demonstrate the novelty and uniqueness of the antimetabolic disorder plant peptides disclosed in this invention, in this example, commercially available bitter melon extracts (Comparative Samples 1 to 7) were subjected to the pretreatment method disclosed in the first example of this invention and analyzed by high-performance liquid chromatography under the same analytical conditions. The chromatograms obtained for Comparative Samples 1 to 7 were combined with the chromatogram shown in Figure 1. The results are shown in Figure 12. The comparison results between the wavelength ranges of Comparative Samples 1 to 7 and the peptides shown in the wavelength ranges (L1) to (L6) disclosed in this invention are summarized in Table 3 below.

[0040] As can be seen from the results in Figure 12 and Table 3, the peptides from the antimetabolic disorder plants disclosed in the present invention contain peptides in the wavelength range (L1) to (L6), whereas Comparative Sample 1 does not contain the wavelength ranges (L1), (L2), and (L6); Comparative Sample 2 does not contain the wavelength ranges (L1), (L4), and (L5); Comparative Sample 3 does not contain the wavelength ranges (L1) to (L6); Comparative Sample 4 does not contain the wavelength ranges (L1) to (L6); Comparative Sample 5 does not contain the wavelength ranges (L1) to (L6); Comparative Sample 6 does not contain the wavelength ranges (L1), (L3) to (L6); and Comparative Sample 7 does not contain the wavelength ranges (L4) to (L6). These results demonstrate that the peptides from the antimetabolic disorder plants disclosed in the present invention are indeed novel and unique and cannot be obtained by isolation from other plant extracts of the same origin.

[0041] The following is an efficacy test conducted to demonstrate that the group of antimetabolic disorder plant peptides disclosed in the present invention has the effect of treating or ameliorating diseases related to abnormalities in blood pressure, blood sugar, and blood lipids.

[0042] First, the human dose was 300 mg / 60 kg adult body weight / day, which was converted to a rat dose according to common knowledge known to those skilled in the art, and the following tests were carried out using various animal models, with the test period being 8 weeks.

[0043] Animal study (1): SD rats were randomly divided into three groups. Group 1 consisted of normal rats. Groups 2 and 3 were type 2 diabetes model rats induced by the simultaneous administration of the drug STZ (25 mg / kg body weight) and a high-fat diet. Group 3 was continuously administered the antimetabolic disorder plant peptides disclosed in this invention throughout the study period. After the eighth week of the study, fasting blood glucose levels and glycated hemoglobin levels were measured for each group of mice. The results are shown in Figures 13 and 14.

[0044] Animal study (2): SD rats were randomly divided into three groups. Group 1 consisted of normal rats, while groups 2 and 3 were type 1 diabetes model rats induced with the drug STZ (75 mg / kg body weight). Group 3 was continuously administered the antimetabolic disorder plant peptides disclosed in the present invention during the study period. After the eighth week of the study, the fasting blood glucose levels of the mice in each group were examined. The results are shown in Figure 15.

[0045] Animal Study (3): SD rats were randomly divided into two groups, and both groups were fed a high-fat diet. After increasing the body weight of each group by 10%, an 8-week study was conducted. The high-fat diet was maintained throughout the study, but only the rats in Group 2 were fed the antimetabolic disorder plant peptides disclosed in this invention. After the study, the rats in each group were examined for body weight, body fat, blood triglycerides, blood total cholesterol, and blood LDL cholesterol. The results are shown in Figures 16 to 20.

[0046] In addition, several subjects were recruited and randomly divided into two groups. Group 1 did not receive the antimetabolic disorder plant peptides disclosed in the present invention, while Group 2 received the antimetabolic disorder plant peptides disclosed in the present invention (300 mg / 60 kg adult body weight / day). Each subject in each group drank 75 g of glucose in a fasting state. Blood glucose levels were measured 0, 30, 60, 90, and 120 minutes after ingestion, and the area under the curve of the oral glucose tolerance test (OGTT AUC) was analyzed 2 hours later. The results are shown in Figures 21 and 22.

[0047] The results of the animal and human tests described above are summarized in Table 3 below. As can be seen from the results in Table 1 and Figures 12 to 21, the antimetabolic disorder plant peptides disclosed in the present invention have the effect of improving both congenital and acquired blood glucose metabolism disorders, and furthermore, they effectively reduced the effects of a high-fat diet on blood lipids and cholesterol, even when high-fat diets are continued. This demonstrates that the antimetabolic disorder plant peptides disclosed in the present invention can indeed simultaneously and effectively improve abnormal metabolic indicators, simultaneously ameliorate diseases related to hyperglycemia, high blood lipids, and obesity, and can also reduce the risk of developing diseases caused by the above-mentioned metabolic disorders.

[0048] Table 3: Efficacy analysis results JPEG2025174570000004.jpg85166

[0049] Furthermore, to demonstrate the difference in efficacy between the antimetabolic disorder plant peptides disclosed in the present invention and compositions that do not contain other peptides in the wavelength ranges (L1) to (L6), the antimetabolic disorder plant peptides of the present invention, Comparative Sample 1, and Comparative Sample 4 were administered to rats with type 2 diabetes, and the changes in body weight, FBS, and HbA1c of the rats in each experimental group were analyzed. The results are shown in Table 5. For details of the experimental procedure, please refer to the description of Animal Test (1) above. The data in Table 5 represent the percentage change in each experimental group compared to the diabetic model rats.

[0050] Furthermore, the antimetabolic disorder plant peptide group of the present invention and comparative sample 4 were administered to rats on a high-fat diet, and the changes in body weight, body fat, triglycerides, and total cholesterol of the rats in each experimental group were analyzed. The results are shown in Table 6. For the experimental procedure, please refer to the explanation in Animal Test (3) above. The data in Table 6 are the percentage changes in each experimental group compared to the diabetic model rats.

[0051] The results in Tables 4 and 5 prove that the group of peptides from plants with metabolic disorders disclosed in the present invention certainly has the effect of significantly improving the control of blood sugar and blood lipids compared to compositions that do not contain other peptide groups represented by the wavelength ranges (L1) to (L6).

[0052] Table 4: Change ratio for diabetic model rats in each experimental group JPEG2025174570000005.jpg21128

[0053] Table 5: Change ratio for diabetic model rats in each experimental group JPEG2025174570000006.jpg26128

[0054] The blood pressure-lowering activity of the angiotensin-converting enzyme (ACE) activity assay using liquid chromatography (LC) was also performed to analyze the activity of angiotensin-converting enzyme (ACE). Specifically, hippuric acid (HA) and histidyl-leucine (His-Leu) are produced by ACE activity, which utilizes hippuric acid as a substrate. Therefore, if the amount of hippuric acid and histidyl-leucine produced is reduced by the addition of a test sample, this indicates that the test sample can effectively treat or ameliorate hypertension. In this example, the blood pressure-lowering ability of the angiotensin-converting enzyme (ACE) activity assay was performed by comparing the amount of hippuric acid produced with and without the addition of the angiotensin-converting enzyme (ACE) activity assay. The ACE activity inhibition rate was calculated by measuring the amount of hippuric acid produced (integrated area) using HPLC analysis. The test results showed that the test group to which the antimetabolic disorder plant peptide group (10 mg / mL) disclosed in the present invention was added had the effect of lowering blood pressure by 30.63% compared to the control group to which the antimetabolic disorder plant peptide group disclosed in the present invention was not added, demonstrating that the antimetabolic disorder plant peptide group disclosed in the present invention does indeed have the ability to lower blood pressure and can be used to prepare compositions for treating or ameliorating hypertension and related diseases.

Claims

1. A group of isolated antimetabolic plant peptides isolated from primary products of plant material, The group of peptides from antimetabolic disorder plants includes peptides having molecular sizes between 700 Da and 2400 Da, which are represented by wavelength ranges (L1) to (L6) in a high performance liquid chromatogram, and the retention time in the wavelength range (L1) is 10.5 to 11.5 minutes, the retention time in the wavelength range (L2) is 12.5 to 13.5 minutes, the retention time in the wavelength range (L3) is 14.5 to 15.5 minutes, the retention time in the wavelength range (L4) is 16.5 to 17.5 minutes, the retention time in the wavelength range (L5) is 17.5 to 18.5 minutes, and the retention time in the wavelength range (L6) is 24.5 to 25.5 minutes; The high performance liquid chromatogram is obtained by subjecting the primary product of the plant raw material to a pretreatment step and then analyzing the primary product using a high performance liquid chromatograph under predetermined analytical conditions; The isolated group of antimetabolic disorder plant peptides is characterized in that the analytical conditions are as follows: a detection wavelength of 220 nm; a separation column of a C18 column; a column temperature of 60°C; an eluent A of 5% acetonitrile containing 0.10% trichloroacetic acid; an eluent B of 95% acetonitrile containing 0.085% trichloroacetic acid; and a mobile phase comprising 10-20% eluent B used for 0-10 minutes, 20-30% eluent B used for 10-25 minutes, and 30-60% eluent B used for 20-60 minutes.

2. The pretreatment step includes: A step a) of dissolving the primary product of the plant raw material in 30% acetonitrile and then subjecting it to ultrasonic extraction to obtain a supernatant; and (b) filtering the supernatant to obtain a filtrate for high performance liquid chromatography.

3. The isolated group of antimetabolic disorder plant peptides according to claim 2, wherein in step b, filtration is carried out using a filter medium having a pore size of 0.20 to 0.25 μm.

4. 10. Use of the isolated antimetabolic disorder plant peptide group according to any one of claims 1 to 3 in the preparation of a composition for preventing or treating hyperlipidemia, hypertension and hyperglycemia.

5. The use according to claim 4, wherein the human dose of the isolated antimetabolic plant peptides contained in said composition is 5 mg / kg / day.

6. 4. Use of the isolated antimetabolic disorder plant peptides according to any one of claims 1 to 3 in the preparation of a diet composition.

7. The use according to claim 6, wherein the human dose of the isolated antimetabolic plant peptides contained in said composition is 5 mg / kg / day.

Images